Snapshot from Sep 12, 2026 at 07:00 UTC. For live data and tracking: View Live
Business manufacturing agreement

Aurigene signs manufacturing supply agreement

Analysis based on 8 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026

Sentiment
40
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The agreement provides long-term revenue visibility for Aurigene and Abbott Laboratories, with revenue expected to commence in 2028, potentially boosting future earnings. The deal enhances Aurigene's CDMO/CMO capabilities, which may strengthen its competitive position in the contract manufacturing market.

Pharmaceuticals Contract manufacturing

Abbott Laboratories — Aurigene Pharmaceutical Services, a wholly owned subsidiary of Abbott Laboratories, has entered into a long-term Manufacturing and Supply Agreement (MSA) with an undisclosed global pharmaceutical company. The agreement covers commercial drug-product manufacturing and supply for markets in the United States, Europe, Canada, and emerging markets. The initial portfolio includes over 20 products spanning sterile injectables, biologics, and topicals, to be manufactured at Aurigene's facilities in India. Technology transfer will occur in phases over the next two to three years, with commercial manufacturing and supply expected to follow. At full commercialization, the portfolio is expected to represent an annual volume of approximately 18 million units, largely injectables, with revenue commencing in calendar year 2028. The agreement strengthens Aurigene's CDMO and CMO capabilities and provides long-term revenue visibility. The counterparty's identity remains undisclosed due to confidentiality obligations.

subs
Aurigene is the primary beneficiary, securing a long-term manufacturing and supply agreement that provides revenue visibility and scales up its drug-product business.
Importance 100.0 Sentiment 70.0
stock
As the parent company, Abbott Laboratories benefits from the subsidiary's strengthened CDMO capabilities and future revenue streams, though the financial impact is expected from 2028.
Importance 80.0 Sentiment 60.0
cnt
India is the manufacturing base for the products under the agreement, highlighting the country's role in pharmaceutical manufacturing and potentially boosting local operations.
Importance 50.0 Sentiment 40.0
cnt
The United States is a key market for the products manufactured under the agreement, representing a significant portion of the supply destination.
Importance 40.0 Sentiment 30.0
per
As CEO of Aurigene, Akhil Rana is the public face of the agreement, highlighting the company's capabilities and strategic value.
Importance 30.0 Sentiment 50.0
loc
Europe is another major market covered by the agreement, contributing to the geographic diversification of Aurigene's supply.
Importance 30.0 Sentiment 30.0
cnt
Canada is included as a market for the products, though its relative importance is smaller compared to the US and Europe.
Importance 20.0 Sentiment 30.0
India strategic partners ↔ United States India views the US as a strategic partner for defense, technology, and regional security, despite facing recent US tarif
India related ↔ Canada
United States trade rivals ↔ Canada The United States views Canada as a key defense partner but also a trade rival, having imposed tariffs and declined to r
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.